Ertapenem resistance of Escherichia coli.
An ertapenem-resistant Escherichia coli isolate was recovered from peritoneal fluid in a patient who had been treated with imipenem/cilastatin for 10 days. Ertapenem resistance may be explained by a defect in the outer membrane protein and production of extended-spectrum beta-lactamase CTX-M-2.
Lartigue
Marie-Frédérique
MF
Université Paris XI, Kremlin-Bicêtre, France.
Poirel
Laurent
L
Poyart
Claire
C
Réglier-Poupet
Hélène
H
Nordmann
Patrice
P
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000935:Antifungal Agents / Q000627:therapeutic use; D015377:Cilastatin / Q000627:therapeutic use; D000077728:Cilastatin, Imipenem Drug Combination; D004338:Drug Combinations; D024901:Drug Resistance, Multiple, Bacterial; D000077727:Ertapenem; D004926:Escherichia coli / Q000187:drug effects*; D004927:Escherichia coli Infections / Q000382:microbiology*; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D016867:Immunocompromised Host; D008875:Middle Aged; D014640:Vancomycin / Q000627:therapeutic use; D047090:beta-Lactams / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D004338:Drug Combinations; D005839:Gentamicins; D047090:beta-Lactams; D015377:Cilastatin; D014640:Vancomycin; D015378:Imipenem; D015725:Fluconazole; D000077728:Cilastatin, Imipenem Drug Combination; D000077727:Ertapenem